LivaNova (NASDAQ:LIVN) Shares Gap Up - What's Next?

Key Points

• LivaNova PLC shares gapped up significantly on Wednesday, opening at $46.10 after closing at $42.61, with the stock trading at $46.95 and a volume of 286,479 shares.
• Multiple analysts have upgraded LivaNova shares recently, with Wolfe Research setting a target price of $60.00, while Needham & Company raised theirs to $64.00, reflecting a generally positive outlook.
• Approximately 97.64% of LivaNova's stock is owned by institutional investors, with firms like Strs Ohio significantly increasing their holdings by over 512% in the 2nd quarter.

LivaNova PLC (NASDAQ:LIVN - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $42.61, but opened at $46.10. LivaNova shares last traded at $46.95, with a volume of 286,479 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on LIVN shares. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a report on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Barclays decreased their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Finally, Robert W. Baird boosted their target price on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Trading Up 8.7%

The company has a market capitalization of $2.52 billion, a PE ratio of -11.34 and a beta of 0.92. The company has a fifty day simple moving average of $44.62 and a 200-day simple moving average of $42.79. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of LIVN. State of Michigan Retirement System lifted its position in LivaNova by 2.3% in the second quarter. State of Michigan Retirement System now owns 13,111 shares of the company's stock valued at $590,000 after buying an additional 300 shares during the last quarter. Strs Ohio lifted its holdings in shares of LivaNova by 512.1% in the 2nd quarter. Strs Ohio now owns 20,200 shares of the company's stock worth $909,000 after acquiring an additional 16,900 shares during the last quarter. Retirement Systems of Alabama raised its holdings in shares of LivaNova by 0.8% in the 2nd quarter. Retirement Systems of Alabama now owns 66,644 shares of the company's stock valued at $3,000,000 after buying an additional 554 shares during the period. State of New Jersey Common Pension Fund D lifted its stake in LivaNova by 11.6% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 43,618 shares of the company's stock worth $1,964,000 after acquiring an additional 4,537 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in LivaNova during the 2nd quarter valued at about $1,713,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.